Last edition
News about
National Institute for Health and Care Research launches a nationwide collaboration to accelerate Parkinson’s research, bringing together academia, NHS and charities to drive faster development of treatments and diagnostics.
Alembic Pharmaceuticals Secures US FDA Nod for Fingolimod Capsules
Alembic Pharmaceuticals receives US FDA approval for fingolimod capsules, expanding access to a key multiple sclerosis treatment in the US market.
OrganaBio LLC, RxMP Therapeutics Partner for cGMP Manufacturing of Novel Bleeding Control Therapy
OrganaBio LLC partners with RxMP Therapeutics to manufacture RMP-402, a next-generation therapy designed to rapidly stop severe bleeding in both civilian and military settings.
Worldwide Clinical Trials Medidata Expand Partnership to Power AI-Driven Clinical Trials
The collaboration between Worldwide Clinical Trials and Medidata integrates Medidata’s AI platform and virtual assistant Dot to enable faster, more connected and data-driven clinical research across global trial operations.
US FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss
US Food and Drug Administration (FDA) approves Regeneron’s Otarmeni, the first AAV-based gene therapy, offering a potential treatment for severe-to-profound hearing loss.
IPC Signs MoUs with PMBI and NIPER Hajipur to Enhance Drug Quality and Safety
IPC signs MoUs with PMBI and NIPER Hajipur to enhance drug quality, pharmacovigilance, research, safety of biologics and emerging therapies, and patient safety across India, including Jan Aushadhi Kendras.
Sun Pharmaceutical Industries Signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries signs a definitive agreement to acquire Organon for USD 14 per share, valuing the deal at USD 11.75B EV. The merger aims to leverage complementary portfolios and global scale for long-term growth.
Thryv Therapeutics Advances THRV-1268 Programme with Phase II/III Trial and FDA Fast Track Status
Thryv Therapeutics initiates Phase II/III clinical testing and secures FDA Fast Track status for THRV-1268, advancing a potential first-in-class therapy for Long QT Syndrome.
Ascletis Pharma Completes US Phase 2 Enrollment for ASC30 GLP-1R Agonist
Ascletis Pharma completes US Phase 2 enrollment for ASC30, an oral GLP-1R agonist for diabetes. The 13-week study evaluates safety, efficacy, and tolerability in 100 patients, with topline results expected in Q3 2026.
ModeX Therapeutics Doses First Patients in Trial of Novel Tetraspecific Therapy for B-Cell Lymphoma
ModeX Therapeutics initiates clinical testing of MDX2003, a next-generation multispecific antibody therapy designed to enhance immune response and improve outcomes in B-cell lymphoma patients.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy